SCHEMBL4408353

SCHEMBL4408353

O=S(=O)(NCc1ccccn1)c1ccc(CN(CCNCc2ccc(Cl)cc2)CCNCc2ccc(Cl)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 1/20 0.52
ALDH1A1 P00352 3/20 0.48
POLB P06746 1/20 0.48
LMNA P02545 2/20 0.47
CXCR3 P49682 1/20 0.47
GAA P10253 1/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MCL1 Q07820 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4417272 0.90 PRMT1 (0.52) PRMT1ALDH1A1POLBLMNAGAA
SCHEMBL4406672 0.89 ALDH1A1 (0.52) PRMT1ALDH1A1POLBLMNAGAA
SCHEMBL4406593 0.89 PRMT1 (0.51) PRMT1ALDH1A1POLBLMNAGAA
SCHEMBL4414888 0.87 PRMT1 (0.49) PRMT1ALDH1A1POLBLMNAGAA
SCHEMBL4412232 0.86 KDM4E (0.51) ALDH1A1POLBGAASMN1; SMN2TSHR
SCHEMBL4409123 0.83 KDM4E (0.51) ALDH1A1POLBSMN1; SMN2TSHRL3MBTL1
SCHEMBL1169464 0.82 PRMT1 (0.74) PRMT1ALDH1A1POLBLMNAGAA
SCHEMBL4404505 0.80 CHRM2 (0.53) ALDH1A1POLBLMNASMN1; SMN2TSHR
SCHEMBL4404474 0.79 MEN1 (0.53) ALDH1A1POLBGAATSHRL3MBTL1
SCHEMBL4405051 0.78 KCNA5 (0.54) ALDH1A1CXCR3GAASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1608352-B1 POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES TAIGEN BIOTECHNOLOGY CO LTD (TW) 2009-12-30 EP disclosed
US-7504422-B2 Polyamine compounds TAIGEN BIOTECHNOLOGY CO. LTD. (TW) 2009-03-17 US disclosed
US-7504422-B2 Polyamine compounds TAIGEN BIOTECHNOLOGY CO. LTD. (TW) 2009-03-17 US disclosed
US-7504422-B2 Polyamine compounds TAIGEN BIOTECHNOLOGY CO. LTD. (TW) 2009-03-17 US disclosed
US-7399776-B2 Polyamine compounds for treating chemokine receptor mediated diseases TAIGEN BIOTECHNOLOGY (TW) 2008-07-15 US disclosed
US-7399776-B2 Polyamine compounds for treating chemokine receptor mediated diseases TAIGEN BIOTECHNOLOGY (TW) 2008-07-15 US disclosed
US-7399776-B2 Polyamine compounds for treating chemokine receptor mediated diseases TAIGEN BIOTECHNOLOGY (TW) 2008-07-15 US disclosed
US-20080058382-A1 POLYAMINE COMPOUNDS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-03-06 US disclosed
US-20080058382-A1 POLYAMINE COMPOUNDS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-03-06 US disclosed
US-20080058382-A1 POLYAMINE COMPOUNDS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-03-06 US disclosed
EP-1608352-A4 POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES TAIGEN BIOTECHNOLOGY CO LTD (TW) 2007-11-28 EP disclosed
EP-1608352-A1 POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES Taigen Biotechnology (TW) 2005-12-28 EP disclosed
US-20050043366-A1 Polyamine compounds for treating chemokine receptor mediated diseases TAIGEN BIOTECHNOLOGY (TW) 2005-02-24 US disclosed
WO-2004089360-A1 POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES TAIGEN BIOTECHNOLOGY (TW) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043366-A1 Polyamine compounds for treating chemokine receptor mediated diseases CCL2, CCR2, CCR5 PRMT1 131/4885ALDH1A1 1278/4885POLB 2466/4885
US-20080058382-A1 POLYAMINE COMPOUNDS SRM, SMS, SMOX PRMT1 4/4885ALDH1A1 422/4885POLB 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.